Business
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida.
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida.","length":507,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Avidity Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Avidity Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":188,"url":"https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CUqGwDlJgRQuW4SSqvStJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79","width":400,"height":188}},"href":"https://mma.prnewswire.com/media/974628/Avidity_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"2026 MDA Clinical & Scientific Congress Presentations","length":57,"tagName":"p"},{"type":"text","content":"Oral Presentation: Del-zota Treatment is Associated with Near Normalization of CK Levels and Improvements in Key Functional Outcomes at 1 Year in Participants with DMD44 (March 11, 2026: 12:30 p.m. – 12:45 p.m. ET)","length":214,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Craig McDonald, M.D., Professor and Chair of the Departments of Physical Medicine and Rehabilitation and Director of the Neuromuscular Disease Clinic at the University of California, Davis, will present 1-year del-zota data from Avidity's Phase 1/2 EXPLORE44 program including near normalization of creatine kinase levels and improvements in functional outcomes in people living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44).","length":473,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":473,"olType":false},{"type":"text","content":"Poster Presentations","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"#138 M: Patient Journey A...